{"entity":{"id":"launxp-biomedical","kind":"company","name":"LaunXP Biomedical","aka":["LaunXP Biomedical Co., Ltd.","朗齊生醫"],"tldr":"LaunXP Biomedical develops new cancer drugs and new uses or forms of existing ones. Its first new compound to reach people is in an early trial in advanced solid tumours in Taiwan.","summary":"LaunXP Biomedical Co., Ltd., at No. 402 Shizheng Road, Xitun District, Taichung, Taiwan, has worked in oncology and metabolic disease since its inception in 2015, according to the company, on two tracks: new chemical entities (505(b)(1)) and repositioned or reformulated existing drugs (505(b)(2)). Its pipeline lists LXP108, a multi-target agent for solid tumours including renal, liver and pancreatic cancer, in phase 1; LXP109 for non-small cell lung cancer with phase 2/3 in planning; LXP107 for acute myeloid leukaemia and LXP103 for metabolic disorders in preclinical work; and LXP105, a 505(b)(2) programme for triple-negative breast cancer with phase 2 in planning. Its registered trial tests LXP1788 injection, given intravenously through an implanted port, in advanced solid tumours. Its first registered cancer trial, NCT06883539, was posted on ClinicalTrials.gov in March 2025. The company publishes investor, governance and shareholder information on its website.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://launxp.com/"},{"label":"Company pipeline","url":"https://launxp.com/research/"},{"label":"ClinicalTrials.gov: phase 1 study of LXP1788 injection in advanced solid tumours (NCT06883539)","url":"https://clinicaltrials.gov/study/NCT06883539"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["drug-repurposing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The registry product LXP1788 is not named on the company website; it may correspond to LXP108, the pipeline programme listed in phase 1 for solid tumours, but this is not confirmed.","The mechanism of LXP108 is described only as multi-target synergistic blockade; no molecular target is recorded. The drug repurposing technology tag reflects the company's stated 505(b)(2) repositioning track.","Whether the company's shares trade on a Taiwan market was not confirmed, so no ticker is recorded and the stage is set as growth.","No financing round was read; none is recorded.","Company website read on 29 October 2026."],"hq":"Taichung","country":"TW","companyType":"biotech","website":"https://launxp.com/","founded":2015,"stage":"growth","investors":[],"funding":[]},"route":"/companies/launxp-biomedical/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/"}]}}